O. Brusco

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.

A. Goldberg, R. Kreisberg, D. Capuzzi, 1998, The American journal of cardiology.

Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.

D. Capuzzi, Yangfeng Wu, Shuiping Zhao, 2008, The American journal of cardiology.

Niacin dosing: Relationship to benefits and adverse effects

D. Capuzzi, C. Intenzo, J. Morgan, 2000, Current atherosclerosis reports.

Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.

D. Capuzzi, H. Bays, Shuiping Zhao, 2014, Journal of Clinical Lipidology.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.